10/19/2011 10:50:40 AM
ROCKLAND, Mass. & NEW YORK--(BUSINESS WIRE)--EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, and Fast Forward LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced a commitment of up to $3 million in 2012 to support innovative early-stage projects directed towards the development of therapies to prevent, treat or reverse nervous system damage in multiple sclerosis (MS). This is the fourth ‘Request for Proposals’ (RFP) issued through the multi-year collaboration between Fast Forward and Merck KGaA to accelerate innovation and commercial development of MS therapies.
comments powered by